Chinese Biotech Start-Up Stemirna Therapeutics Raises $14M Series A Round

Stemirna Therapeutics, a Chinese biotech start-up focusing on RNA technology-based drug development, has raised nearly RMB100 million (US$14.16 million) in a serious A round of financing.

China Money Network

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech


Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!


Already have an account or paid subscription? Log in

LEAVE A REPLY